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Abstract
Introduction: Acute respiratory distress syndrome (ARDS) with concomitant impairment of oxygenation and
decarboxylation represents a complex problem in patients with increased intracranial pressure (ICP). Permissive
hypercapnia is not an option to obtain and maintain lung-protective ventilation in the presence of elevated ICP.
Pumpless extracorporeal lung assist (pECLA) devices (iLA Membrane Ventilator; Novalung, Heilbronn, Germany) can
improve decarboxylation without aggravation associated with invasive ventilation. In this pilot series, we analyzed
the safety and efficacy of pECLA in patients with ARDS and elevated ICP after severe traumatic brain injury (TBI).
Methods: The medical records of ten patients (eight male, two female) with severe ARDS and severe TBI concurrently
managed with external ventricular drainage in the neurointensive care unit (NICU) were retrospectively analyzed. The
effect of pECLA on enabling lung-protective ventilation was evaluated using the difference between plateau pressure
and positive end-expiratory pressure, defined as driving pressure (ΔP), during the 3 days preceding the implant of
pECLA devices until 3 days afterward. The ICP threshold was set at 20 mmHg. To evaluate effects on ICP, the volume of
daily cerebrospinal fluid (CSF) drainage needed to maintain the set ICP threshold was compared pre- and postimplant.
Results: The ΔP values after pECLA implantation decreased from a mean 17.1 ± 0.7 cm/H2O to 11.9±0.5 cm/H2O
(p = 0.011). In spite of this improved lung-protective ventilation, carbon dioxide pressure decreased from 46.6 ±
3.9 mmHg to 39.7 ± 3.5 mmHg (p = 0.005). The volume of daily CSF drainage needed to maintain ICP at 20 mmHg
decreased significantly from 141.5 ± 103.5 ml to 62.2 ± 68.1 ml (p = 0.037).
Conclusions: For selected patients with concomitant severe TBI and ARDS, the application of pECLA is safe and
effective. pECLA devices improve decarboxylation, thus enabling lung-protective ventilation. At the same time,
potentially detrimental hypercapnia that may increase ICP is avoided. Larger prospective trials are warranted to further
elucidate application of pECLA devices in NICU patients.
Introduction
Acute respiratory distress syndrome (ARDS), according
to the recent Berlin definition, is defined as impaired
oxygenation caused by acute, diffuse, inflammatory lung
injury [1]. Though inflammatory in nature, ARDS is
often triggered by aspiration and traumatic lung injury
in the context of patients with severe brain injuries and
impaired consciousness. Thus, it is not uncommon in
neurocritically ill patients, and it is a predictor of
in-hospital mortality [2]. The management of ARDS
comprises mechanical ventilation with low tidal volume
(VT), a plateau pressure (Pplat) <30 cm/H2O, and positive
end-expiratory pressure (PEEP) adjusted to the fraction
of inspired oxygen (FiO2) [3]. This lung-protective venti-
lation (LPV) concept may cause hypercapnia, which is
tolerated as long as oxygenation is adequate and pH re-
mains >7.1 [4, 5]. However, hypercapnia impairs cerebral
hemodynamics and autoregulation of cerebral blood flow
per se. In patients with traumatic brain injury (TBI), the
latter can aggravate a preexisting alteration of cerebral
autoregulation [6–9]. This may result in an increase of
intracranial pressure (ICP), with potentially deleterious
effects for the injured brain. The treatment of patients
with concomitant TBI and ARDS is challenging because
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the management of ICP requires avoiding permissive
hypercapnia. Therefore, alternative interventions are re-
quired to treat both pathologies appropriately. Pumpless
extracorporeal lung assist (pECLA) devices can improve
decarboxylation, thus enabling LPV while stabilizing
carbon dioxide pressure (pCO2) at tolerable levels for
patients requiring rigorous ICP management [10–12].
In this retrospective patient cohort, we endeavored to
evaluate the use of a pECLA device (iLA Membrane
Ventilator; Novalung, Heilbronn, Germany) in patients
with severe brain injury and concomitant ARDS in a
neurointensive care unit (NICU).
Methods
Patient selection
We retrospectively analyzed the medical records of ten
patients (eight male, two female) treated in our NICU
between 2011 and 2014. The data collection and analysis
and publication of the results were approved by the local
ethics committee (ethics committee of Heinrich Heine
University Düsseldorf, Chairman Prof. Kröncke, study
4516). No consent from the patients for inclusion of
their data in this analysis was necessary, so it was not
obtained. Individual details potentially jeopardizing
patients’ anonymity are omitted.
The decision regarding pECLA treatment for patients
with TBI (Abbreviated Injury Scale score >3) was based
on the clinical constellation of mild to moderate ARDS
refractory to conservative measures according to the
Berlin definition with insufficient oxygenation despite
LPV and poor or unapparent decarboxylation (pCO2 >
45 mmHg) with concomitant elevated ICP >20 mmHg
measured continuously with an external ventricular
catheter (EVD) [1, 13, 14]. Conservative interventions
used to control elevated ICP included deep sedation
without myorelaxation, prone positioning with 30-degree
elevated head rest, and drainage of cerebrospinal fluid
(CSF) via the EVD.
Ventilator therapy focused on achieving a low VT of
6 ml/kg of predicted body weight and avoiding excessive
ventilation pressure >30 cm/H2O. We aimed at normal-
izing pCO2 levels between 35 mmHg and 45 mmHg.
Clinical interventions comprised an increase in respira-
tory rate to enable adequate ventilation as long as indi-
vidual expiratory time remained sufficient. When this
yielded no satisfactory effect on pCO2, we increased the
driving pressure (ΔP) by increasing the Pplat.
Application of extracorporeal carbon dioxide elimination
The use of extracorporeal lung assist is an established
supportive therapeutic strategy in ARDS [15]. We used
the iLA Membrane Ventilator [11]. Under ultrasono-
graphic control, a 15-French, 90-mm arterial cannula
was inserted into a femoral artery and a second cannula
(17 French, 140 mm) was placed in the opposite femoral
vein using the Seldinger technique. Driving force for the
perfusion of the membrane system is the patients’
arteriovenous pressure difference. Thus, systemic blood
pressure must be sufficient to enable blood to flow
through the pECLA system at 1.3–1.7 L/min. Through
an oxygen supply line connected to the inflow site of the
membrane oxygenator, a continuous oxygen flow of
6–10 L/min is established to achieve carbon dioxide
extraction from the blood.
Partial thromboplastin time (PTT) >50 s is recom-
mended to prevent blood clotting in the system; however,
all surfaces in contact with circulating blood are heparin-
coated to reduce the risk of coagulation. All patients
received continuous intravenous heparin infusions with a
target PTT ranging from 50 to 60 s. The effect of
anticoagulation was controlled every 12 h, and the
heparin infusion was adjusted accordingly.
pECLA device was discontinued when decarboxylation
improved and ICP was stable enough to allow the
reduction of sedation and spontaneous breathing. Sub-
sequently, the continuous oxygen flow of the membrane
oxygenator was diminished to reduce carbon dioxide
extraction, and the pECLA device was removed when
pCO2 remained stable.
Statistical analysis
Ventilation parameters [ΔP, Pplat, mean ventilation pres-
sure (Pmean), PEEP, VT, pCO2, pH] from 3 days preceding
pECLA device implant until 3 days afterward were com-
pared. All ventilation-related variables, such as VT in
milliliters, Pplat in cm/H2O, Pmean in cm/H2O, PEEP in
cm/H2O, blood pH level, and ΔP in cm/H2O (defined as
Pplat minus PEEP) were recorded half-hourly [16]. Add-
itionally, the ratio of oxygen pressure (pO2) to FiO2
(pO2/FiO2) was calculated every 4–6 h based on arterial
blood gas analysis and the ventilator setting. Mean arterial
pressure (MAP) was recorded continuously for each
patient. To calculate mean values, a single reading every
30 min was taken. Last, the fluid balance of each patient
was recorded daily for a 24-h period.
To quantify the effects of ICP management, the
volume of daily CSF drainage was compared before and
after the pECLA device was implanted. The amount of
drained CSF necessary to maintain the set ICP threshold
of 20 mmHg was recorded every 24 h.
Statistical analysis was performed using IBM SPSS ver-
sion 15.1.1 software (IBM, Armonk, NY, USA). To identify
differences between relevant parameters before and after
the pECLA device was implanted, the Wilcoxon signed-
rank test for related samples was applied. Significance was
accepted at a level of p < 0.05. Depending on the variable,
means with standard deviations or medians with inter-
quartile ranges (IQRs) are given.
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Results
The mean patient age was 40.2 ± 16.5 years, and all
patients developed ARDS between 2 and 7 days after
admission (median 4.5 days; IQR 3.3–5.8 days). The
pECLA device was implanted a median of 1.5 (IQR 1–2)
days after ARDS was diagnosed and was removed after a
median of 8 days (IQR 7–9 days). The relevant patient
characteristics and data are shown in Table 1.
Implant of the pECLA device facilitated a significant
decrease of pCO2 from 46.6 ± 3.9 mmHg to 39.7 ±
Table 1 Patient characteristics
Patient Age (yr) ARDS diagnosis (days after admission) pECLA device implant after ARDS diagnosis (days) pECLA device treatment (days)
1 39 7 2 12
2a 61 6 2 7
3 40 4 1 5
4a 35 2 2 7
5 13 5 1 12
6 53 3 1 4 (6)b
7 53 5 2 8
8 50 6 1 8
9 53 4 2 8
10 50 3 1 9
aPatient died within 30 days after admission
bPatient was treated after day 4 with venovenous extracorporeal membrane oxygenation because of acute decreasing oxygenation
Fig. 1 Changes in carbon dioxide pressure (pCO2), pH, mean arterial pressure (MAP), oxygen pressure to fraction of inspired oxygen (pO2/FiO2)
ratio, and respiratory rate after implant of the pumpless extracorporeal lung assist device. a After implant (post) of the pumpless extracorporeal
lung assist (pECLA) device, pCO2 was significantly reduced compared with before (pre)implant. b Simultaneously, pH increased significantly
postimplant as compared with preimplant. The pO2/FiO2 ratio (c), MAP (d), and respiratory rate (e) remained unchanged before and after implant
of the pECLA device.
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3.5 mmHg (p = 0.005), and pH rose from 7.42 ± 0.04 to
7.46 ± 0.03 (p = 0.021) (Fig. 1a, b). The pO2/FiO2 ratio
remained unchanged after implant of the pECLA device
(Fig. 1c). MAP was kept stable over the treatment period
(Fig. 1d), and fluid was kept at a positive balance of
1500–2000 ml daily to stabilize patients’ hemodynamics.
Respiratory rate showed no significant change, but a
slight decrease was seen (Fig. 1e).
The mean volume of daily CSF drainage needed to
maintain ICP <20 mmHg decreased significantly from
141.5 ± 103.5 ml to 62.2 ± 68.1 ml (p = 0.037) (Fig. 2).
Mean Pplat was significantly reduced [28.0 ± 1.0 cm/
H2O to 25.2 ± 0.5 cm/H2O, 95 % (CI) of the difference
2.6–3.1 cm/H2O; p < 0.001], and PEEP was increased sig-
nificantly (11.5 ± 0.7 cm/H2O to 13.7 ± 0.2 cm/H2O,
95 % CI of the difference 2.1–2.4 cm/H2O; p < 0.001).
Both interventions caused a decrease of ΔP from a mean
of 17.1 ± 0.7 cm/H2O to 11.9 ± 0.5 cm/H2O (p = 0.011),
whereas Pmean remained unchanged (19.3 ± 0.7 cm/H2O
to 19.2 ± 0.3 cm/H2O; p = 0.726) (Fig. 3).
In our cohort, one patient developed right heart failure
4 days after implant of the pECLA device. The pECLA
device was immediately discontinued, and the patient
was treated with a venovenous extracorporeal membrane
oxygenation (ECMO) system. She recovered without
sequelae and was discharged from the intensive care unit
after 20 days.
Discussion
In this report of a patient cohort with ARDS and TBI
treated with implant of a pECLA device, we describe
several important findings. First, pECLA is a safe and ef-
fective tool to enable LPV in patients with ARDS in the
presence of severe brain injury. Second, in the critical
situation of elevated ICP and concomitant demand for
adjusted ventilation, the use of pECLA enables better
ICP control under optimized ventilator settings. Third,
the better control of ICP, as reflected in the reduced ne-
cessity to drain CSF, results from optimized pCO2 levels
and reduced ΔP and occurs regardless of Pmean.
Though most patients with TBI die as a result of the
underlying pathology or secondary complications rather
than because of respiratory failure per se, ARDS contrib-
utes significantly to poor outcome and increased risk of
death in these patients [2, 17]. The fundamental treat-
ment approach in ARDS is to achieve adequate oxygen-
ation and decarboxylation by optimizing mechanical
ventilation. However, mechanical ventilation can induce
lung injury and thus exacerbate the pathology itself, and
it can also contribute to dysfunction of other organs [18,
19]. In order to reduce alveolar overdistension, which is
the most frequent ventilator-induced lung injury, the use
of low VT ventilation (i.e., LPV) is the preferred ap-
proach [3, 20]. LPV can cause hypercapnia, which is usu-
ally well-tolerated and thus referred to as permissive
hypercapnia [21]. In addition to avoiding high peak in-
spiratory pressures, the concept of LPV is to use high
PEEP to improve oxygenation and reduce or prevent
atelectasis [22, 23].
In neurosurgical patients with TBI, permissive hyper-
capnia cannot be tolerated easily. Hypercapnia increases
cerebral blood flow by cerebral vasodilation. More
specifically, with increasing pCO2, the autoregulatory
pressure range is decreased and, depending on the pCO2
level, cerebral autoregulation is significantly impaired
[3, 8, 9]. In severe hypercapnia with pCO2 > 70 mmHg,
the pressure–flow relationship can approximate a linear
relationship, as demonstrated in animal experiments [24].
Thus, hypercapnia in these vulnerable patients can aggra-
vate blood flow dysregulation and cause detrimental
increases in ICP. Extracorporal carbon dioxide removal
using pECLA is effective in patients in a tenuous situation
of severe lung and brain injury [10, 25]. pCO2 is effectively
reduced to normal levels and can be controlled by adjust-
ing the oxygen sweep flow to avoid unwanted hypocapnia.
Normalization of pCO2 is accompanied by increased pH
and avoidance of respiratory acidosis. This yields a signifi-
cant reduction in drained CSF as a surrogate for improved
ICP control. Interestingly, mean airway pressure does not
contribute to this effect. After pECLA device implant,
inspiratory pressure is decreased, but PEEP is increased,
to improve oxygenation. As a consequence, mean airway
Fig. 2 Daily cerebrospinal fluid (CSF) drainage. The mean volume of
drained CSF per 24 h from 3 days preceding implant of the pumpless
extracorporeal lung assist (pECLA) device until 3 days afterward is
shown. The arrow marks the time of implant of the pECLA device, and
the whiskers represent the standard deviation
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pressure does not change significantly. Therefore,
improved ICP control can be attributed predominantly to
the normalization of pCO2. In ARDS, the combination of
low VT and higher PEEP is superior to low VT with lower
PEEP [26]. Though application of PEEP in patients with
brain injury remains controversial, a judicious adaption of
PEEP to the demand in patients with lung injury is feasible
[27]. High peak pressures do have a deleterious effect on
cerebral hemodynamics, however, and can be avoided in
this setting [7].
An important limitation of our analysis is its retro-
spective nature; thus, residual confounding parameters
might have been missed. In addition, the number of pa-
tients is too small to allow generalizability of the results
or to provide any meaningful outcome data. However,
the main aim of this study was to provide data on the
safety and efficacy of this intervention.
In this context, it is important to recognize that, for
pECLA treatment, systemic anticoagulation to avoid
clotting of the filter membrane is recommended. In
patients with brain injury, this may increase the risk of
decompensating intracerebral hematomas. However, in
our series, no complications (cerebral or extracerebral)
attributable to anticoagulation were seen. Besides, owing
to heparin-coating of the extracorporeal circuit, low-dose
systemic anticoagulation is sufficient to avoid clotting of
the extracorporeal circuit, thereby minimizing the risk of
bleeding complications. In patients with extraordinarily
high risk of bleeding, even a complete abdication of antic-
oagulation in venovenous ECMO was shown to be safe
and feasible [28]. Also, elevated ICP and CSF production
are multifactorial processes, and in the small, retrospective
setting of the present study, confounding hemodynamic
or metabolic effects contributing to the reduction in CSF
drainage with the use of pECLA may have been missed.
Owing to the relevant shunt volume of approximately
1500 ml of blood per minute over the extracorporeal
circuit, a relevant increase in right heart preload occurs.
This may have contributed to the right heart failure in
one of our patients. This patient had no known preexist-
ing cardiac disease; however, the patient was obese (body
mass index 33 kg/m2), which might have contributed to
reduced right ventricular capacity.
Conclusions
For selected patients with concomitant severe brain and
lung injury, the application of pECLA is effective to
avoid hypercapnia and respiratory acidosis, thus enabling
application of LPV guidelines as well as effective ICP
control. Large prospective trials are necessary to further
Fig. 3 Changes in plateau pressure (Pplat), mean pressure (Pmean), and positive end-expiratory pressure (PEEP) after implant of the pumpless extracorporeal
lung assist device. a The respiratory rate was gradually increased before pumpless extracorporeal lung assist (pECLA) device implant, corresponding to
the increase of airway pressure, and then decreased afterward. b Ventilation parameters for Pplat, Pmean, and PEEP every 30 min are illustrated.
After implant of the pECLA device (arrow), Pplat was significantly reduced (p < 0.001), whereas PEEP was increased significantly (p < 0.001). Pmean
remained unchanged
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elucidate the application of pECLA devices and the
influence of different ventilation pressures on ICP and
outcome in NICU patients.
Key messages
 pECLA is a safe and effective tool to enable LPV in
patients with ARDS and TBI.
 pECLA effectively reduces pCO2 and normalizes pH
in patients vulnerable to hypercapnia.
 pECLA enables better ICP control under optimized
ventilator settings than without extracorporeal
decarboxylation.
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